Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.31 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26168785 | 0.99 | PLA2G2A (0.31) | PLA2G2APLA2G4APIM1CSNK2A2CSNK2B | |
| SCHEMBL26169017 | 0.98 | PLA2G2A (0.33) | SIRT2SIRT1PLA2G2APLA2G4APIM1 | |
| SCHEMBL26169222 | 0.98 | PLA2G2A (0.33) | SIRT2SIRT1PLA2G2APLA2G4APIM1 | |
| SCHEMBL26168517 | 0.98 | PLA2G2A (0.33) | SIRT2SIRT1PLA2G2APLA2G4APIM1 | |
| SCHEMBL23947829 | 0.97 | SIRT2 (0.32) | SIRT2SIRT1PLA2G2APLA2G4APIM1 | |
| SCHEMBL25504813 | 0.97 | PLA2G2A (0.32) | SIRT2SIRT1PLA2G2APLA2G4AMMP12 | |
| SCHEMBL26168487 | 0.97 | PLA2G2A (0.33) | SIRT2SIRT1PLA2G2APLA2G4APIM1 | |
| SCHEMBL23814075 | 0.97 | PLA2G2A (0.33) | SIRT2SIRT1PLA2G2APLA2G4APIM1 | |
| SCHEMBL26168740 | 0.96 | ATM (0.34) | SIRT2SIRT1PLA2G2APLA2G4APIM1 | |
| SCHEMBL26168738 | 0.96 | ATM (0.34) | SIRT2SIRT1PLA2G2APLA2G4APIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172062-A1 | ORGANIC ELECTROLUMINESCENT APPARATUS | MERCK PATENT GMBH (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230172062-A1 | ORGANIC ELECTROLUMINESCENT APPARATUS | MERCK PATENT GMBH (DE) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172062-A1 | ORGANIC ELECTROLUMINESCENT APPARATUS | SLC29A1, SLC19A2, NUDT1 | SIRT2 3104/4885SIRT1 3775/4885PLA2G2A 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.